Evidence map›Paper›PMID 38675440›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate.

Falguni Basuli, Olga Vasalatiy, Jianfeng Shi, Kelly C Lane, Freddy E Escorcia, Rolf E Swenson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. MIB guides: [Molecular imaging and biology · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Falguni BasuliChemistry and Synthesis Center, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA.
Olga VasalatiyChemistry and Synthesis Center, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA.
Jianfeng ShiChemistry and Synthesis Center, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA.
Kelly C LaneChemistry and Synthesis Center, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA.
Freddy E EscorciaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-0727-3242
Rolf E SwensonChemistry and Synthesis Center, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-7804-7202

Funding

Imaging Probe Development CenterZICHL005090 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SWENSON, ROLF · 2011 to 2025
$22.2M
Engineering HCC-selective PET agentZIABC011800 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ESCORCIA, FREDDY · 2018 to 2025
$10.6M
NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Desferrioxamine B (DFO) is the clinical standard chelator for preparing zirconium-89 labeled antibodies. In the current study, the stabilities of a zirconium-89 labeled panitumumab (PAN; Vectibix

Indexed as

BCN-DOTA-GADFODFO*DOTAPANstability

Identifiers

PMID38675440
PMCPMC11053460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.